FDA Approves Bayer's Sunharbo as First Factor XIa Inhibitor for Repeat Stroke Prevention

Bayer estimates that about 795,000 people in the United States have a stroke each year, and the company says about one in five people who have had a stroke will have another within five years. Reuters reported on November 9 that the U.S. total is about 800,000 a year and that recurrence rates have stayed persistently high for 20 years. Those figures frame the arrival of a drug designed to reduce the risk of a second stroke.

Noncardioembolic ischemic strokes are a substantial part of that burden. Ashkan Shoamanesh, co-principal investigator at the Population Health Research Institute, said they account for about 45% of the 12 million strokes worldwide each year, according to NeurologyLive. Existing clot preventers such as Eliquis and Xarelto block factor Xa rather than factor XIa. Reuters reported on November 9 that asundexian is the first approved treatment designed to prevent harmful clots by blocking factor XIa. Bayer says factor XIa inhibition reduces amplification of thrombin generation, targeting pathological clotting with lesser impact on normal hemostasis in preclinical models.

The clinical case rests on OCEANIC-STROKE, a phase 3 trial that enrolled 12,327 adults within 72 hours of a noncardioembolic ischemic stroke or high risk transient ischemic attack. Patients received asundexian or placebo on top of planned single or dual antiplatelet therapy. Ischemic stroke occurred in 6.2% of asundexian patients versus 8.4% on placebo, a 26% relative reduction over a median 14.2 months. The composite of cardiovascular death, myocardial infarction or stroke was 9.2% versus 11.1%.

The approval is narrower than the broadest hopes for the drug. Sunharbo is cleared for adults after a recent mild to moderate noncardioembolic ischemic stroke or high risk TIA, with antiplatelet therapy, and it is not approved for stroke prevention in atrial fibrillation. The FDA granted Fast Track and Priority Review designations. The FDA flagged increased severe bleeding in patients older than 75 and during the first 90 days, and the label requires withholding at least 24 hours before elective surgery and for 24 hours after thrombolysis.

Key Facts

The U.S. Food and Drug Administration announced on November 9, 2026, that it had approved Sunharbo (asundexian) 50 mg tablets, once daily, with antiplatelet therapy to reduce stroke risk in adults after a recent mild to moderate noncardioembolic ischemic stroke or high risk TIA. The agency called it the first factor XIa inhibitor approved in the United States. Hylton V. Joffe, director of the FDA's Office of Cardiology, Hematology, Endocrinology, and Nephrology, called it a meaningful advance. The approval went to Bayer HealthCare Pharmaceuticals Inc. in Whippany, N.J.

Reuters reported on November 9 that the FDA cleared asundexian as a once daily pill for preventing repeat strokes in patients who have already had a stroke or a high risk TIA. Reuters also reported that China's drug regulator approved Sunharbo in late October, making the U.S. action a second major market clearance rather than a global first.

NeurologyLive reported on November 9 that the trial randomized 6,162 patients to asundexian and 6,165 to placebo. Eligible patients had an NIHSS score of 15 or less plus a nonlacunar infarct on imaging, a history of atherosclerosis, or cerebrovascular plaque. Ischemic stroke occurred in 6.2% versus 8.4% (hazard ratio 0.74; 95% confidence interval 0.65 to 0.84; P less than .001), and the composite of cardiovascular death, myocardial infarction or stroke was 9.2% versus 11.1% (hazard ratio 0.83; 95% confidence interval 0.74 to 0.92).

Safety data were reassuring on the primary bleeding measure but not uniform. ISTH major bleeding occurred in 1.9% of asundexian patients versus 1.7% on placebo (hazard ratio 1.10; 95% confidence interval 0.85 to 1.44; P equals .46). Bayer reported major bleeding at 1.6 versus 1.5 per 100 patient years, while gastrointestinal bleeding was higher at 2.7 versus 2.1 per 100 patient years (hazard ratio 1.3; 95% confidence interval 1.0 to 1.6). Diarrhea was the most common adverse reaction, reported in 3.4% versus 2.8%.

Bayer announced on November 9 that it expects U.S. shipping to begin in mid to late November, with hospitals and pharmacies able to order shortly after. The drug is under review by the European Medicines Agency and Japan's Ministry of Health, Labour and Welfare. China's National Medical Products Administration approved it on October 26, 2026. The drug is not recommended in moderate or severe hepatic impairment and is not approved for stroke prevention in atrial fibrillation.

Analysis

The approval is a genuine first, but the word first can oversell what the data show. The 26% relative reduction is meaningful, yet the absolute difference in ischemic stroke was 2.2 percentage points over a median of 14.2 months, from 8.4% to 6.2%. The drug still leaves many patients with a second stroke, and it must be added to antiplatelet therapy rather than replacing it. Those limits are not arguments against approval. They are the terms on which clinicians will decide whom to treat.

The bigger picture here is that the approval validates a specific bet: that blocking factor XIa can reduce thrombosis without causing the same level of bleeding as factor Xa inhibitors. The trial supports that idea on its primary safety endpoint, because ISTH major bleeding was 1.9% versus 1.7% and not significantly different. But the FDA flag on severe bleeding in people older than 75 and in the first 90 days complicates the story. Stroke disproportionately affects older adults, and that is precisely the group in which the risk benefit calculation is hardest.

Commercial expectations are being reset around that nuance. Reuters reported on November 10 that Bayer shares rose as much as 2% to a 2026 high of EUR 57.78 after the approval, supporting CEO Bill Anderson's turnaround of the pharmaceuticals division. Bayer once targeted peak sales above EUR 5 billion, a forecast made obsolete after the drug failed a 2023 trial in atrial fibrillation. Jefferies now sees U.S. and EU market potential of about EUR 2 billion and estimates the drug could be suitable for roughly 40% of stroke patients. Those figures describe a substantial product, but not the multibillion dollar franchise Bayer originally imagined.

The competitive field adds another layer. Novartis is developing abelacimab, and Bristol Myers and Johnson and Johnson are developing milvexian, according to Reuters. Neither has reported late stage stroke prevention data. Anderson said Bayer reached the market about a year earlier than planned and that its competitors do not even have phase 3 results yet, according to the November 10 Reuters report. That lead is real, but it is a lead in execution, not proof that asundexian will win on outcomes. The 2023 atrial fibrillation failure is a reminder that a mechanism can look promising in one setting and disappoint in another.

Why It Matters

For patients, the practical change is a new option after the first stroke, when fear of a second event is highest. About one in 10 patients has another stroke within one year, according to Shoamanesh in NeurologyLive, and Bayer says about one in five will have another within five years. A 26% relative reduction matters at that scale, even if the absolute benefit is concentrated in certain patients.

For the health system, cost and safety monitoring will shape uptake. At about $748.50 per month, widespread use would be costly, and Jefferies' estimate that roughly 40% of stroke patients could be suitable suggests a large potential population. The label's restrictions, including avoidance in moderate or severe hepatic impairment and the 24 hour holds around surgery and thrombolysis, add operational complexity. Hospitals and pharmacies will need pathways for ordering, patient selection and follow up.

For Bayer, the approval is a strategic reprieve. Xarelto revenue is declining after patent loss and generic competition, and the company is counting on asundexian to offset that erosion. The U.S. launch, handled by Bayer on its own for long term use, keeps promotion in house. But the same safety questions that limit use in older patients could also limit peak sales. The market will judge the drug on real world persistence and bleeding rates, not only on the 26% figure from a controlled trial.

Next Up

The next regulatory decisions are in Europe and Japan. Bayer said the drug is under review by the European Medicines Agency and Japan's Ministry of Health, Labour and Welfare. China has already approved it, giving Bayer a second market outside the United States. U.S. shipping will begin in mid to late November, so hospitals and pharmacies could have product within weeks.

The clinical agenda is equally important. Longer term data will show whether the bleeding signal in patients older than 75 persists outside the trial and whether the benefit holds across different antiplatelet regimens. The FDA flag on increased severe bleeding during the first 90 days makes early monitoring a priority. The 2023 failure in atrial fibrillation also means the company and clinicians must resist extending the drug beyond its approved population.